The Back-Room Injection Business

The pharmacy should stop preparing sterile injections immediately. A laminar airflow hood in an unclassified back room with a door opening to the retail aisle is not a compliant sterile compounding environment. Sterile compounding requires a classified buffer area and a primary engineering control that is certified on the required schedule; a certification sticker expired 14 months ago means the hood cannot be assumed to provide ISO 5 conditions. Cardboard, a sink in the preparation area, no cleaning schedule, no temperature and humidity logs, and a technician with a cold preparing injections without a mask are all serious deficiencies. The pharmacist checking syringes from the doorway is not adequate supervision or verification. The owner's 'no complaints' argument does not establish compliance. The pharmacy may continue nonsterile dispensing, but sterile compounding must remain suspended until the facility, equipment, policies, and trained personnel meet current standards.

Methotrexate is a hazardous drug. Hazardous drug compounding requires controls that are separate from nonhazardous sterile compounding, including appropriate engineering controls, negative pressure relative to adjacent areas, external venting, PPE, and validated deactivation and cleaning procedures. Wiping the hood surface with alcohol between products is not adequate decontamination, and using the same hood immediately after methotrexate creates a risk of cross-contamination for injectable vitamin and ketorolac patients and occupational exposure for staff. The pharmacy should not compound hazardous drugs in that hood unless it has a compliant hazardous drug program. If it cannot meet those requirements, it should stop hazardous compounding and refer patients elsewhere. This is separate from the general sterile compounding deficiencies and requires its own corrective plan.

The pharmacist-in-charge should immediately suspend sterile compounding, quarantine affected supplies, and document the decision. Staff should be retrained on sterile technique, garb, cleaning, and exclusion of ill personnel. The hood must be recertified, the room brought into compliance or compounding outsourced, and temperature and humidity monitoring, cleaning logs, and standard operating procedures established. The pharmacist should review whether any patient may have been harmed and, with the owner and legal counsel, determine whether patient notification or Board reporting is required. The Board should be contacted if the pharmacy has been operating outside its permit or applicable compounding standards. The pharmacy should not resume until it can demonstrate compliance. The rural location may create access problems, but distance to a hospital does not lower the sterility standard.